Orca-T

BIOLOGICAL5 trials

Conditions

Acute LeukemiaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Myeloid LeukemiaHematologic MalignanciesLeukemia, Myeloid, AcuteMixed Phenotype Acute Leukemia

Phase 1

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruitingNCT04013685

Orca Biosystems, Inc.Acute Leukemia, Acute Lymphoid Leukemia, Acute Myeloid Leukemia +3

Start: 2019-11-21End: 2027-04-01Updated: 2026-08-14

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

RecruitingNCT06551584

Stanford UniversityAcute Lymphoid Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia +1

Start: 2025-12-01End: 2026-12-01Target: 24Updated: 2026-06-23

Phase 2

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

RecruitingNCT07216443

Orca Biosystems, Inc.Leukemia, Myeloid, Acute, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes

Start: 2025-12-09End: 2028-12-01Target: 80Updated: 2026-07-07

Phase 3

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruitingNCT05316701

Orca Biosystems, Inc.Acute Leukemia, Acute Lymphoid Leukemia, Acute Myeloid Leukemia +4

Start: 2022-06-21End: 2026-07-01Updated: 2026-03-04

Unknown Phase

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

NCT07346105

Orca Biosystems, Inc.Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Hematologic Malignancies +2

Updated: 2026-07-24

2025-12-121 citations

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Blood2025-11-03

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood2025-11-03

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood2025-11-03

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood2024-11-05

Treatment of acute myeloid leukemia with Orca-T.

Journal of Clinical Oncology2024-06-01

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients &gt; 55 Years Old with Hematologic Malignancies

Blood2023-11-022 citations

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Blood2023-11-022 citations

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood2022-11-1517 citations

Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Blood2022-11-151 citations

S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES

HemaSphere2022-06-011 citations

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Blood2021-11-0510 citations

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors

Blood2021-11-05

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Blood2020-11-049 citations

Orca-T

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers